Structure-based discovery and binding site analysis of histamine receptor ligands

References

• Fourneau E, Bovet D. Recherches sur l’action sympathicolytique d’un nouveau dérivé du dioxane. Arch Int Pharmacodyn Ther. 1933;46:178–191.
   Google Scholar
• Molinder HK. The development of cimetidine: 1964-1976. A human story. J Clin Gastroenterol. 1994;19:248–254.
   PubMed Web of Science ®Google Scholar
• Nauta WT, Harms AF Proceedings of the international pharmacol. meeting, 3rd edn. vol 7. Oxford: Pergamon Press. p 305; 1968.
   Google Scholar
• Henderson R, Unwin PN. Three-dimensional model of purple membrane obtained by electron microscopy. Nature. 1975;257:28–32.
   PubMed Web of Science ®Google Scholar
• Henderson R, Baldwin JM, Ceska TA, et al. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol. 1990;213:899–929. DOI:10.1016/S0022-2836(05)80271-2
   PubMed Web of Science ®Google Scholar
• Grigorieff N, Ceska TA, Downing KH, et al. Electron-crystallographic refinement of the structure of bacteriorhodopsin. J Mol Biol. 1996;259:393–421. DOI:10.1006/jmbi.1996.0328
   PubMed Web of Science ®Google Scholar
• Ter Laak AM, Timmerman H, Leurs R, et al. Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-agonists: Asp116 (TM3) has a constitutive role in receptor stimulation. J Comput Aided Mol Des. 1995;9:319–330.
   PubMed Web of Science ®Google Scholar
• Wieland K, Ter Laak AM, Smit MJ, et al. Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem. 1999;274:29994–30000.
   PubMed Web of Science ®Google Scholar
• Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289:739–745.
   PubMed Web of Science ®Google Scholar
• Kiss R, Kovári Z, Keseru GM. Homology modelling and binding site mapping of the human histamine H1 receptor. Eur J Med Chem. 2004;39:959–967. DOI:10.1016/j.ejmech.2004.07.009
   PubMed Web of Science ®Google Scholar
• Axe FU, Bembenek SD, Szalma S. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. J Mol Graph Model. 2006;24:456–464. DOI:10.1016/j.jmgm.2005.10.005
   PubMed Web of Science ®Google Scholar
• Shin N, Coates E, Murgolo NJ, et al. Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mol Pharmacol. 2002;62:38–47.
   PubMed Web of Science ®Google Scholar
• Schnell D, Strasser A, Seifert R. Comparison of the pharmacological properties of human and rat histamine H(3)-receptors. Biochem Pharmacol. 2010;80:1437–1449. DOI:10.1016/j.bcp.2010.07.027
   PubMed Web of Science ®Google Scholar
• Lim HD, Jongejan A, Bakker RA, et al. Phenylalanine 169 in the second extracellular loop of the human histamine H4 receptor is responsible for the difference in agonist binding between human and mouse H4 receptors. J Pharmacol Exp Ther. 2008;327:88–96. DOI:10.1124/jpet.108.140343
   PubMed Web of Science ®Google Scholar
• Shimamura T, Shiroishi M, Weyand S, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011;475:65–70. DOI:10.1038/nature10236
   PubMed Web of Science ®Google Scholar
• de Graaf C, Kooistra AJ, Vischer. HF, et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H1 receptor. J Med Chem. 2011;54:8195–8206. DOI:10.1021/jm2011589
   PubMed Web of Science ®Google Scholar
• Prasad Ratnala VR, Hulsbbergen FB, de Groot HJ, et al. Analysis of histamine and modeling of ligand-receptor interactions in the histamine H(1) receptor for magic angle spinning NMR studies. Inflamm Res. 2003;52:417–423. DOI:10.1007/s00011-003-1195-3
   PubMed Web of Science ®Google Scholar
• Cordova-Sintjago TC, Fang L, Bruysters M, et al. Molecular determinants of ligand binding at the human histamine H1 receptor: site-directed mutagenesis results analyzed with ligand docking and molecular dynamics studies at H1 homology and crystal structure models. J Chem Pharm Res. 2012;4:2937–2951.
   PubMedGoogle Scholar
• Shah JR, Mosier PD, Roth BL, et al. Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009;17:6496–6504. DOI:10.1016/j.bmc.2009.08.016
   PubMed Web of Science ®Google Scholar
• Bruysters M, Jongejan A, Gillard M, et al. Pharmacological differences between human and guinea pig histamine H1 receptors: Asn84 (2.61) as key residue within an additional binding pocket in the H1 receptor. Mol Pharmacol. 2005;67:1045–1052. DOI:10.1124/mol.104.008847
   PubMed Web of Science ®Google Scholar
• Strasser A, Wittmann HJ. LigPath: a module for predictive calculation of a ligand’s pathway into a receptor-application to the gpH1-receptor. J Mol Model. 2007;13:209–218. DOI:10.1007/s00894-006-0152-9
   PubMed Web of Science ®Google Scholar
• Strasser A, Wittmann HJ. Analysis of the activation mechanism of the guinea-pig Histamine H1-receptor. J Comput Aided Mol Des. 2007;21:499–509. DOI:10.1007/s10822-007-9131-1
   PubMed Web of Science ®Google Scholar
• Sato M, Hirokawa T. Extended template-based modeling and evaluation method using consensus of binding mode of GPCRs for virtual screening. J Chem Inf Model. 2014;54:3153–3161. DOI:10.1021/ci500499j
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Y, Pan Y, et al. Computational analysis of structure-based interactions for novel H₁-Antihistamines. Int J Mol Sci. 2016;17:pii:E129. DOI:10.3390/ijms17010129
   Web of Science ®Google Scholar
• Kooistra AJ, Vischer HF, McNaught-Flores D, et al. Function-specific virtual screening for GPCR ligands using a combined scoring method. Sci Rep. 2016;6:28288. DOI:10.1038/srep28288
   PubMed Web of Science ®Google Scholar
• Sun X, Li Y, Li W, et al. Computational investigation of interactions between human H2 receptor and its agonists. J Mol Graph Model. 2011;29:693–701. DOI:10.1016/j.jmgm.2010.12.001
   PubMed Web of Science ®Google Scholar
• Kelley MT, Bürckstümmer T, Wenzel-Seifert K, et al. Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type agonists. Mol Pharmacol. 2001;60:1210–1225.
   PubMed Web of Science ®Google Scholar
• Yao BB, Hutchins CW, Carr TL, et al. Molecular modeling and pharmacological analysis of species-related histamine H(3) receptor heterogeneity. Neuropharmacology. 2003;44:773–786.
   PubMed Web of Science ®Google Scholar
• Kuder K, Łażewska D, Latacz G, et al. Chlorophenoxy aminoalkyl derivatives as histamine H(3)R ligands and antiseizure agents. Bioorg Med Chem. 2016;24:53–72. DOI:10.1016/j.bmc.2015.11.021
   PubMed Web of Science ®Google Scholar
• Rai BK, Tawa GJ, Katz AH, et al. Modeling G protein-coupled receptors for structure-based drug discovery using low-frequency normal modes for refinement of homology models: application to H3 antagonists. Proteins. 2010;78:457–473. DOI:10.1002/prot.22571
   PubMed Web of Science ®Google Scholar
• Lorenzi S, Mor M, Bordi F, et al. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Bioorg Med Chem. 2005;13:5647–5657. DOI:10.1016/j.bmc.2005.05.072
   PubMed Web of Science ®Google Scholar
• Kim SK, Fristrup P, Abrol R, et al. Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials. J Chem Inf Model. 2011;51:3262–3274. DOI:10.1021/ci200435b
   PubMed Web of Science ®Google Scholar
• Feng Z, Hou T, Li Y. Docking and MD study of histamine H4R based on the crystal structure of H1R. J Mol Graph Model. 2013;39:1–12. DOI:10.1016/j.jmgm.2012.10.003
   PubMed Web of Science ®Google Scholar
• Bajda M, Kuder KJ, Lażewska D, et al. Dual-acting diether derivatives of piperidine and homopiperidine with histamine H(3) receptor antagonistic and anticholinesterase activity. Arch Pharm (Weinheim). 2012;345:591–597. DOI:10.1002/ardp.201200018
   PubMed Web of Science ®Google Scholar
• Schlegel B, Laggner C, Meier R, et al. Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des. 2007;21:437–453. DOI:10.1007/s10822-007-9127-x
   PubMed Web of Science ®Google Scholar
• Dastmalchi S, Hamzeh-Mivehroud M, Ghafourian T, et al. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists. J Mol Graph Model. 2008;26:834–844. DOI:10.1016/j.jmgm.2007.05.002
   PubMed Web of Science ®Google Scholar
• Uveges AJ, Kowal D, Zhang Y, et al. The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J Pharmacol Exp Ther. 2002;301:451–458
   PubMed Web of Science ®Google Scholar
• Levoin N, Calmels T, Poupardin-Olivier O, et al. Refined docking as a valuable tool for lead optimization: application to histamine H3 receptor antagonists. Arch Pharm (Weinheim). 2008;341:610–623. DOI:10.1002/ardp.200800042
   PubMed Web of Science ®Google Scholar
• Jacobsen ML, Rimvall K, Hastrup S, et al. XXXII annual meeting of the European histamine research society. Noordwijkerhout: Netherlands; 2003.
   Google Scholar
• Abrol R, Bray JK, Goddard WA. Bihelix: towards de novo structure prediction of an ensemble of G-protein coupled receptor conformations. Proteins. 2012;80:505–518. DOI:10.1002/prot.23216
   PubMed Web of Science ®Google Scholar
• Sirci F, Istyastono EP, Vischer HF, et al. Virtual fragment screening: discovery of histamine H3 receptor ligands using ligand-based and protein-based molecular fingerprints. J Chem Inf Model. 2012;52:3308–3324. DOI:10.1021/ci3004094
   PubMed Web of Science ®Google Scholar
• Levoin N, Labeeuw O, Krief S, et al. Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists. Bioorg Med Chem. 2013;21:4526–4529. DOI:10.1016/j.bmc.2013.05.035
   PubMed Web of Science ®Google Scholar
• Christopher F, Thangam EB, Suresh MX. A bioinformatics search for selective histamine h4 receptor antagonists through structure-based virtual screening strategies. Chem Biol Drug Des. 2012;79:749–759. DOI:10.1111/j.1747-0285.2012.01336.x
   PubMed Web of Science ®Google Scholar
• Kiss R, Noszál B, Rácz A, et al. Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. Eur J Med Chem. 2008;43:1059–1070. DOI:10.1016/j.ejmech.2007.07.014
   PubMed Web of Science ®Google Scholar
• Jójárt B, Kiss R, Viskolcz B, et al. Activation mechanism of the human histamine H4 receptor–an explicit membrane molecular dynamics simulation study. J Chem Inf Model. 2008;48:1199–1210. DOI:10.1021/ci700450w
   PubMed Web of Science ®Google Scholar
• Jongejan A, Lim HD, Smits RA, et al. Delineation of agonist binding to the human histamine H4 receptor using mutational analysis, homology modeling, and ab initio calculations. J Chem Inf Model. 2008;48:1455–1463. DOI:10.1021/ci700474a
   PubMed Web of Science ®Google Scholar
• Schultes A, Nijmeijer S, Engelhardt H, et al. Mapping histamine H4 receptor–ligand binding modes. Med Chem Commun. 2013;4:193–204. DOI:10.1039/C2MD20212C
   Web of Science ®Google Scholar
• Engelhardt H, Schultes S, De Graaf C, et al. Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode. J Med Chem. 2013;56:4264–4276. DOI:10.1021/jm301886t
   PubMed Web of Science ®Google Scholar
• Łażewska D, Więcek M, Ner J, et al. Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands. Eur J Med Chem. 2014;83:534–546. DOI:10.1016/j.ejmech.2014.06.032
   PubMed Web of Science ®Google Scholar
• Kiss R, Kiss B, Könczöl Á, et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem. 2008;51:3145–3153. DOI:10.1021/jm7014777
   PubMed Web of Science ®Google Scholar
• Istyastono EP, Nijmeijer S, Lim HD, et al. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. J Med Chem. 2011;54:8136–8147. DOI:10.1021/jm201042n
   PubMed Web of Science ®Google Scholar
• Deml KF, Beermann S, Neumann D, et al. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor. Mol Pharmacol. 2009;76:1019–1030. DOI:10.1124/mol.109.058651
   PubMed Web of Science ®Google Scholar
• Wittmann HJ, Elz S, Seifert R, et al. N (α)-Methylated phenylhistamines exhibit affinity to the hH(4)R-a pharmacological and molecular modelling study. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:287–299. DOI:10.1007/s00210-011-0671-5
   PubMed Web of Science ®Google Scholar
• Igel P, Geyer R, Strasser A, et al. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists. J Med Chem. 2009;52:6297–6313. DOI:10.1021/jm900526h
   PubMed Web of Science ®Google Scholar
• Pappalardo M, Shachaf N, Basile L, et al. Sequential application of ligand and structure based modeling approaches to index chemicals for their hH4R antagonism. PLoS One. 2014;9:e109340. DOI:10.1371/journal.pone.0109340
   Google Scholar
• Tarcsay A, Paragi G, Vass M, et al. The impact of molecular dynamics sampling on the performance of virtual screening against GPCRs. J Chem Inf Model. 2013;53:2990–2999. DOI:10.1021/ci400087b
   PubMed Web of Science ®Google Scholar
• Vass M, Schmidt É, Horti F, et al. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. Eur J Med Chem. 2014;77:38–46. DOI:10.1016/j.ejmech.2014.02.034
   PubMed Web of Science ®Google Scholar
• Kiss R, Jójárt B, Schmidt É, et al. Identification of novel Histamine H4 ligands by virtual screening on molecular dynamics ensembles. Mol Inform. 2014;33:264–268. DOI:10.1002/minf.201300072
   PubMed Web of Science ®Google Scholar
• Gatica EA, Cavasotto CN. Ligand and decoy sets for docking to G protein-coupled receptors. J Chem Inf Model. 2012;52:1–6. DOI:10.1021/ci200412p
   PubMed Web of Science ®Google Scholar
• Farrens DL, Altenbach C, Yang K, et al. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science. 1996;274:768–770
   PubMed Web of Science ®Google Scholar
• Beuming T, Sherman W. Current assessment of docking into GPCR crystal structures and homology models: successes, challenges, and guidelines. J Chem Inf Model. 2012;52:3263–3277. DOI:10.1021/ci300411b
   PubMed Web of Science ®Google Scholar